The ASAH1 Gene Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME) genetic test is a specialized diagnostic examination available at DNA Labs UAE, designed to identify mutations in the ASAH1 gene. These mutations are responsible for causing SMA-PME, a rare, autosomal recessive neurodegenerative disorder. The condition is characterized by progressive muscle weakness and wasting (spinal muscular atrophy) alongside myoclonic seizures (epilepsy). The test is crucial for early detection and management of the disease, offering insights into potential treatment paths and helping in family planning for those with a history of SMA-PME. The cost of the test is set at 4400 AED, reflecting the comprehensive nature of the analysis and the sophisticated technology employed to ensure accurate results.
The ATP7A gene spinal muscular atrophy distal X-linked genetic test is a specialized diagnostic procedure aimed at identifying mutations in the ATP7A gene, which are linked to a rare form of spinal muscular atrophy (SMA) known as distal X-linked SMA. This condition affects the motor neurons in the spinal cord, leading to muscle weakness and atrophy primarily in the distal muscles, which are those farthest from the center of the body, such as hands and feet. It is an X-linked disorder, meaning it is associated with the X chromosome, and typically affects males more severely than females.
DNA Labs UAE offers this comprehensive genetic test for individuals who may be at risk of carrying or expressing the mutation associated with this form of SMA. The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect any genetic abnormalities in the ATP7A gene.
The cost of the ATP7A gene spinal muscular atrophy distal X-linked genetic test at DNA Labs UAE is 4400 AED. This price reflects the sophisticated nature of the genetic analysis and the specialized expertise required to interpret the results accurately. By undergoing this test, individuals and families can gain valuable insights into their genetic health, enabling them to make informed decisions about their medical care and potential treatment options.
The BICD2 Gene Spinal Muscular Atrophy Lower Extremity Autosomal Dominant Type 2 (SMA-LED2) genetic test is a specialized diagnostic tool used to detect mutations in the BICD2 gene, which are known to cause SMA-LED2. This condition is characterized by muscle weakness and atrophy predominantly affecting the lower limbs, often leading to difficulties in walking and mobility. It is inherited in an autosomal dominant pattern, meaning that only one copy of the altered gene is sufficient to cause the disorder.
The test is conducted at DNA Labs UAE, a reputable facility known for its comprehensive genetic testing services. The process involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the lab to identify any mutations in the BICD2 gene.
The cost of the BICD2 Gene Spinal Muscular Atrophy Lower Extremity Autosomal Dominant Type 2 genetic test is 4400 AED. While the price may seem steep, it's important to consider the value of the information it provides, which can be crucial for early diagnosis, management, and treatment planning for affected individuals and their families. Early detection through this genetic test can significantly improve the quality of life for those with SMA-LED2 by allowing for timely interventions and support.
The DYNC1H1 gene plays a crucial role in the development and function of the nervous system, and mutations in this gene can lead to various neurological conditions, including Spinal Muscular Atrophy Lower Extremity-Predominant Type 1 (SMA-LED1), an autosomal dominant disorder. This particular form of spinal muscular atrophy is characterized by muscle weakness and atrophy primarily affecting the lower limbs. Unlike other forms of SMA, SMA-LED1 shows a pattern of inheritance where only one copy of the mutated gene from either parent is sufficient to cause the disorder.
To diagnose this condition, a genetic test is available at DNA Labs UAE, which specifically looks for mutations in the DYNC1H1 gene associated with SMA-LED1. The test is a crucial tool for confirming the diagnosis, understanding the risk of passing the condition to offspring, and guiding management and treatment decisions. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify mutations in the DYNC1H1 gene. Conducting this test at DNA Labs UAE ensures access to state-of-the-art genetic testing services, provided by a team of professionals specialized in genetic disorders.
The ATP2B3 Gene Spinocerebellar Ataxia Type 1 X-Linked Genetic Test is a specialized diagnostic procedure aimed at detecting mutations in the ATP2B3 gene, which are linked to the development of Spinocerebellar Ataxia Type 1 (SCA1), a condition affecting the cerebellum and leading to progressive coordination problems. This particular form of ataxia is inherited in an X-linked pattern, meaning the gene responsible for the condition is located on the X chromosome.
SCA1 is characterized by a range of symptoms, including difficulty with coordination and balance, speech impairments, and eye movement abnormalities. Early detection through genetic testing can be crucial for managing the condition, allowing for personalized treatment plans and genetic counseling for affected families.
The test is conducted at DNA Labs UAE, a leading facility in genetic diagnostics and research. The cost for the ATP2B3 Gene Spinocerebellar Ataxia Type 1 X-Linked Genetic Test is 4400 AED. The process involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the lab for the presence of mutations in the ATP2B3 gene. Results from this test can provide invaluable information for affected individuals and their families regarding the management of the condition and the risk of transmission to future generations.
The AP5Z1 gene SPG48 genetic test is a specialized diagnostic tool designed to identify mutations in the AP5Z1 gene, which are linked to a rare condition known as Spastic Paraplegia 48 (SPG48). This condition is part of a group of disorders known as hereditary spastic paraplegias, which are characterized by progressive stiffness and weakness of the legs. The test is crucial for individuals displaying symptoms of SPG48 or those with a family history of the disorder, as it can confirm the diagnosis and assist in the development of a tailored management plan.
Conducted at DNA Labs UAE, a leading facility in genetic testing, the test involves analyzing the patient's DNA sample, typically obtained through a blood draw, to detect any genetic abnormalities in the AP5Z1 gene. The process is comprehensive, employing advanced genetic sequencing technologies to ensure accurate and reliable results.
The cost of the AP5Z1 gene SPG48 genetic test at DNA Labs UAE is set at 4400 AED. While the price might seem significant, the value of the test lies in its ability to provide crucial insights into the patient's condition, thereby enabling informed decisions about treatment and management options. It's an investment in health that could significantly impact the quality of life for individuals affected by SPG48, offering them a clearer path towards managing their condition.
The TECPR2 gene SPG49 genetic test is a specialized diagnostic procedure aimed at detecting mutations in the TECPR2 gene, which are associated with a rare neurodegenerative disorder known as spastic paraplegia 49 (SPG49). This condition is part of a group of genetic disorders known as hereditary spastic paraplegias (HSP), characterized by progressive stiffness and contraction (spasticity) in the lower limbs. SPG49, in particular, is distinguished by additional features that may include intellectual disability, developmental delays, and problems with the autonomic nervous system.
DNA Labs UAE offers this genetic test, providing a critical tool for the accurate diagnosis of SPG49. The test involves analyzing the patient's DNA to look for specific mutations in the TECPR2 gene that are indicative of the disorder. Early and precise diagnosis through this test can facilitate appropriate clinical management, counseling, and support for affected individuals and their families.
The cost of the TECPR2 gene SPG49 genetic test at DNA Labs UAE is 4400 AED. This price reflects the specialized nature of the test and the comprehensive analysis required to identify the genetic mutations associated with SPG49. Patients interested in undergoing this test are advised to consult with their healthcare provider to understand the implications of the results and to discuss the best course of action based on the outcome.
The AP4E1 gene, associated with Spastic Paraplegia 51 (SPG51), plays a crucial role in the development and function of the nervous system. Mutations in this gene can lead to a range of neurological disorders, including SPG51, a form of hereditary spastic paraplegia. This condition is characterized by progressive weakness and spasticity of the legs, often accompanied by developmental delay, intellectual disability, and other neurological complications.
To diagnose this condition, the AP4E1 Gene SPG51 Genetic Test is conducted. This specialized genetic test is designed to detect mutations in the AP4E1 gene, providing crucial information for diagnosis, management, and genetic counseling of affected individuals and their families.
The test is available at DNA Labs UAE, a leading facility in genetic testing and personalized medicine. DNA Labs UAE employs state-of-the-art technology and adheres to international standards in genetic testing, ensuring accurate and reliable results.
The cost of the AP4E1 Gene SPG51 Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to identify mutations in the AP4E1 gene, offering individuals and families critical insights into their genetic health and aiding in the management of SPG51.
The AP4S1 gene SPG52 genetic test is a specialized diagnostic procedure designed to detect mutations in the AP4S1 gene, which are linked to Spastic Paraplegia 52 (SPG52). SPG52 is a rare genetic disorder characterized by progressive weakness and stiffness of the legs, part of a group of disorders known as hereditary spastic paraplegias. These mutations can lead to various neurological symptoms, including developmental delay, intellectual disability, and problems with movement and coordination.
Conducted at DNA Labs UAE, a leading facility in genetic testing and analysis, this test is pivotal for early diagnosis and management of SPG52. It involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed for specific mutations in the AP4S1 gene. The results can provide valuable information for affected individuals and their families, including insights into the condition's progression, potential treatments, and the risk of passing the disorder to future generations.
The cost of the AP4S1 gene SPG52 genetic test at DNA Labs UAE is 4400 AED. This price reflects the comprehensive analysis and expertise required to accurately identify mutations in the AP4S1 gene and provide a conclusive diagnosis. For families and individuals facing the possibility of SPG52, this test represents a crucial step towards understanding and managing the condition.
The VPS37A Gene SPG53 Genetic Test is a specialized diagnostic examination designed to identify mutations in the VPS37A gene, which are associated with Spastic Paraplegia 53 (SPG53), a rare form of hereditary spastic paraplegia. This condition typically manifests in early childhood and is characterized by progressive weakness and spasticity of the lower limbs, leading to mobility difficulties and other neurological symptoms.
The test is crucial for families with a history of SPG53, offering them an opportunity for early diagnosis, which is essential for managing symptoms, planning treatment strategies, and understanding the risk for future generations. It involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory for any genetic alterations in the VPS37A gene.
Performed at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, the test ensures accuracy and confidentiality. The cost of the VPS37A Gene SPG53 Genetic Test is set at 4400 AED, reflecting the sophisticated technology and expertise required to conduct this specialized analysis. For families affected by hereditary spastic paraplegia, this test represents a critical step towards personalized medicine and improved quality of life.
